NextCure (NASDAQ:NXTC) Upgraded at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH upgraded shares of NextCure (NASDAQ:NXTC) from a neutral rating to a buy rating in a research report sent to investors on Friday, MarketBeat Ratings reports. The brokerage currently has $18.00 price target on the stock.

A number of other equities analysts have also weighed in on NXTC. Piper Sandler set a $15.00 target price on NextCure and gave the stock an “overweight” rating in a research note on Tuesday, July 15th. Weiss Ratings restated a “sell (d-)” rating on shares of NextCure in a research report on Friday, October 31st. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, NextCure presently has an average rating of “Moderate Buy” and an average target price of $23.00.

NextCure Price Performance

Shares of NASDAQ NXTC traded down $0.13 during mid-day trading on Friday, reaching $8.84. 13,129 shares of the company’s stock were exchanged, compared to its average volume of 50,028. NextCure has a 52 week low of $2.69 and a 52 week high of $19.20. The firm has a 50-day moving average price of $7.29 and a two-hundred day moving average price of $6.10. The firm has a market capitalization of $23.68 million, a price-to-earnings ratio of -0.37 and a beta of 1.48.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($3.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.06) by $0.84. As a group, sell-side analysts forecast that NextCure will post -1.87 EPS for the current fiscal year.

Institutional Trading of NextCure

An institutional investor recently raised its position in NextCure stock. Pfizer Inc grew its stake in NextCure, Inc. (NASDAQ:NXTC) by 29.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,891,763 shares of the company’s stock after purchasing an additional 433,213 shares during the quarter. NextCure comprises about 0.2% of Pfizer Inc’s holdings, making the stock its 17th biggest holding. Pfizer Inc owned about 6.74% of NextCure worth $909,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.